Improving Weight Loss in Healthy Adults With Overweight and Obesity: An Artificial Intelligence-assisted Dietary Prediction and Prevention System With Continuous Glucose Monitoring

January 31, 2026 updated by: Jocelyn Chew, National University Health System, Singapore
This study aims to examine the effectiveness of a novel dietary lapse prediction and prevention self-regulation app called the eating behaviour trigger-response inhibition program (eTRIP), and the addition of continuous glucose monitoring (CGM), on healthy eating and weight loss in people with overweight and obesity.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Singapore
      • Singapore, Singapore, 117597
        • National University of Singapore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. are 21-65 years old
  2. have BMI ≥23 kg/m2
  3. can comprehend the English language
  4. uses a smartphone that can download apps
  5. are willing to perform continuous glucose monitoring (CGM) using the Dexcom continuous glucose monitoring system
  6. willing to travel to the National University of Singapore (NUS)
  7. able to provide informed consent

Exclusion Criteria:

  1. are using/intend to use other apps for weight loss;
  2. are pregnant or lactating (as it would affect weight change and caloric needs)
  3. are diagnosed severe mental disorders (e.g. major depressive disorder and schizophrenia)
  4. are on prescribed meal replacements or pharmacotherapy
  5. have serious medical conditions
  6. are scheduled for any kind of surgery within the next 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: eTRIP smartphone application
Intervention group 1 involves using the eating behaviour trigger-response inhibition program(eTRIP) smartphone application for 10 weeks, where participants will need to take pictures of their food items as part of their food logging and may also engage with app-based activities to build self-regulatory skills in sticking to their weight loss plans. Additionally, participants will also apply a continuous glucose monitoring (CGM) sensor on their arm and taught how to scan the CGM sensor so that they can monitor their glucose levels for the first 10 days.
Behavioral: eTRIP
Intervention group 1 involves using the eating behaviour trigger-response inhibition program(eTRIP) smartphone application for 10 weeks, where participants will need to take pictures of their food items as part of their food logging and may also engage with app-based activities to build self-regulatory skills in sticking to their weight loss plans. Additionally, participants will also apply a continuous glucose monitoring (CGM) sensor on their arm and taught how to scan the CGM sensor so that they can monitor their glucose levels for the first 10 days.
Sham Comparator: FatSecret smartphone application
Intervention group 2 involves using the FatSecret smartphone application for participants to monitor their calorie intake, without any continuous glucose monitoring.
Other: FatSecret
Intervention group 2 involves using the FatSecret smartphone application for participants to monitor their calorie intake, without any continuous glucose monitoring.
No Intervention: Control
Control group will not receive any smartphone application or continuous glucose monitoring.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Height
Time Frame: At weeks 0, 10 and 24.
Taken using a wall mounted measuring tape.
At weeks 0, 10 and 24.
Weight
Time Frame: At weeks 0, 10 and 24.
Taken using InBody 120
At weeks 0, 10 and 24.
Waist Circumference
Time Frame: At weeks 0, 10 and 24.
Taken using a measuring tape.
At weeks 0, 10 and 24.
BMI
Time Frame: At weeks 0, 10 and 24.
Taken using InBody 120
At weeks 0, 10 and 24.
Self regulation of Eating Behaviour Questionnaire (SREBQ)
Time Frame: At weeks 0, 10 and 24.
The Self-Regulation of Eating Behaviour Questionnaire (SREBQ) is a validated self-administered instrument used to assess individuals' self-regulation in relation to eating behavior. It evaluates the extent to which individuals monitor, control, and regulate their eating behaviors in everyday contexts. Higher scores indicate greater self-regulation of eating behavior.
At weeks 0, 10 and 24.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Health Questionnaire-2 (PHQ-2)
Time Frame: At weeks 0, 10 and 24.
The Patient Health Questionnaire - 2 item (PHQ-2) is a validated self-administered screening questionnaire used to assess the frequency of depressive symptoms over the past two weeks. Higher scores indicate greater depressive symptom severity.
At weeks 0, 10 and 24.
Euro Quality of life 5 Dimensions-5 Levels (EQ-5D-5L)
Time Frame: At weeks 0, 10 and 24.
The EuroQol 5 Dimensions - 5 Levels (EQ-5D-5L) is a standardized self-administered instrument used to assess health-related quality of life. It measures five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with five response levels.
At weeks 0, 10 and 24.
Generalized Anxiety Disorder 2-item (GAD-2)
Time Frame: At weeks 0, 10 and 24.
The Generalized Anxiety Disorder - 2 item (GAD-2) is a validated self-administered screening questionnaire used to assess the frequency of core anxiety symptoms over the past two weeks. Higher scores indicate greater anxiety symptom severity.
At weeks 0, 10 and 24.
Percentage Body Fat
Time Frame: At weeks 0, 10 and 24.
Taken using InBody 120.
At weeks 0, 10 and 24.
Body Fat Mass
Time Frame: At weeks 0, 10 and 24.
Taken using InBody 120.
At weeks 0, 10 and 24.
Three Factor Eating Questionnaire (TFEQ)
Time Frame: At weeks 0, 10 and 24.
The Three-Factor Eating Questionnaire (TFEQ) is a validated self-administered instrument used to assess eating-related behaviors. It measures three domains: cognitive restraint of eating, uncontrolled eating, and emotional eating. Higher scores indicate greater levels of the respective eating behavior.
At weeks 0, 10 and 24.
International Physical Activity Questionnaire Short-Form (IPAQ-SF)
Time Frame: At weeks 0, 10 and 24.
The International Physical Activity Questionnaire - Short Form (IPAQ-SF) is a validated self-administered questionnaire used to assess self-reported physical activity levels. It captures the frequency and duration of walking, moderate-intensity activity, and vigorous-intensity activity performed over the past 7 days.
At weeks 0, 10 and 24.
Self-Report Behavioural Automaticity Index (SRBAI)
Time Frame: At weeks 0, 10 and 24.
The Self-Report Behavioural Automaticity Index (SRBAI) is a validated self-administered questionnaire used to assess the automaticity of behavior. It evaluates the extent to which a behavior is performed automatically, with little conscious thought or deliberation. Higher scores indicate greater behavioral automaticity.
At weeks 0, 10 and 24.
Consideration of Future Consequences Scale (CFCS-6)
Time Frame: At weeks 0, 10 and 24.
The Consideration of Future Consequences Scale - 6 item (CFCS-6) is a validated self-administered questionnaire used to assess the extent to which individuals consider the potential future outcomes of their current behaviors. It evaluates the degree to which individuals weigh immediate versus future consequences when making decisions. Higher scores indicate greater consideration of future consequences.
At weeks 0, 10 and 24.
Skeletal Muscle Mass
Time Frame: At weeks 0,10 and 24.
Taken using InBody 120.
At weeks 0,10 and 24.
Visceral Fat Level
Time Frame: At weeks 0, 10 and 24.
Taken using InBody 120.
At weeks 0, 10 and 24.
Big Five Inventory - 44 item (BFI-44)
Time Frame: At weeks 0, 10 and 24.
The Big Five Inventory - 44 item (BFI-44) is a validated self-administered questionnaire used to assess personality traits across five domains: openness, conscientiousness, extraversion, agreeableness, and neuroticism. Higher scores indicate greater expression of the respective personality traits.
At weeks 0, 10 and 24.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National University Health System, Singapore

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 22, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

June 24, 2025

First Submitted That Met QC Criteria

January 31, 2026

First Posted (Actual)

February 9, 2026

Study Record Updates

Last Update Posted (Actual)

February 9, 2026

Last Update Submitted That Met QC Criteria

January 31, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NUS-IRB-2023-597

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe